ERX-41

• Description :

  ERX-41 is an orally active and stereospecific small molecule targeting to lysosomal acid lipase A (LIPA) . ERX-41 induces endoplasmic reticulum (ER) stress resulting in cell death, indicating a function independent of LIPA but dependent on its ER localization. ERX-41 involves in a targeted strategy for solid tumors[1].

• UNSPSC :

  12352005

• Target :

  Lipase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/erx-41.html

• Purity :

  98.25

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CC(OCCO)=C(C=C1)[N+]([O-])=O)NC2=C(C=C(C=C2)C(NC3=C(C=C(C=C3)C(N[C@H]4CC[C@@H](CC4)C)=O)OCC(C)C)=O)OCC(C)C

• Molecular Formula :

  C38H48N4O9

• Molecular Weight :

  704.81

• References & Citations :

  [1]Liu X, et al. Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress. Nat Cancer. 2022 Jul;3 (7) :866-884.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2440087-54-5]